Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 18/20 | 0.63 |
| ▸ | ATP4B | P51164 | 18/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9292234 | 0.85 | ATP4A (0.54) | ATP4AATP4BMAPTNPC1RAB9A | |
| SCHEMBL11021937 | 0.74 | ATP4A (0.54) | ATP4AATP4BMAPTNPC1RAB9A | |
| Zaltidine SCHEMBL534302 | 0.74 | ATP4A (0.54) | ATP4AATP4BMAPTNPC1RAB9A | |
| Zaltidine SCHEMBL635743 | 0.72 | ATP4A (0.53) | ATP4AATP4BMAPTNPC1RAB9A | |
| SCHEMBL9298276 | 0.71 | ATP4A (0.57) | ATP4AATP4BMAPTNPC1RAB9A | |
| SCHEMBL6985595 | 0.71 | MAPT (0.57) | ATP4AATP4BMAPTNPC1RAB9A | |
| Bromide SCHEMBL826907 | 0.71 | MAPT (0.97) | ATP4AATP4BMAPTNPC1RAB9A | |
| Zaltidine SCHEMBL3605309 | 0.71 | ATP4A (0.39) | ATP4AATP4BNPC1RAB9A | |
| SCHEMBL9297745 | 0.70 | ATP4A (0.55) | ATP4AATP4BMAPTNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL9298145 | 0.70 | ATP4A (0.56) | ATP4AATP4BMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8277782-B2 | Antiinflammatory agent, metalloproteinase inhibitor, anti-oxidant and modifier of cell redox status, vitamins, inhibitor of activation of nuclear factor kappa beta | THE PROCTER & GAMBLE COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| EP-1294367-B1 | ORAL COMPOSITIONS COMPRISING HOST-RESPONSE MODULATING AGENT | PROCTER & GAMBLE (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20060193790-A1 | Promoting whole body health | THE PROCTER & GAMBLE COMPANY | 2006-08-31 | — | — | US | disclosed |
| US-20050042283-A1 | Histamine and CCK2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer | UNIVERSITY OF MASSACHUSETTS (US) | 2005-02-24 | — | — | US | disclosed |
| WO-2005007107-A2 | HISTAMINE AND CCK2/GASTRIN RECEPTOR BLOCKADE IN THE TREATMENT OF ACID-PEPTIC DISEASE AND CANCER | UNIVERSITY OF MASSACHUSETTS (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-1189662-A1 | COMBINATION FOR TREATING WEIGHT GAIN ASSOCIATED WITH ANTIPSYCHOTIC USE COMPRISING AN ATYPICAL ANTIPSYCHOTIC AND AN H2 ANTAGONIST | ELI LILLY AND COMPANY (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000074784-A1 | COMBINATION FOR TREATING WEIGHT GAIN ASSOCIATED WITH ANTIPSYCHOTIC USE COMPRISING AN ATYPICAL ANTIPSYCHOTIC AND AN H2 ANTAGONIST | ELI LILLY AND COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| US-5364616-A | Use of H-2 antagonists for treatment of gingivitis | THE PROCTER & GAMBLE COMPANY (US) | 1994-11-15 | — | — | US | disclosed |
| US-5294433-A | Dentistry | THE PROCTER & GAMBLE COMPANY (US) | 1994-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060193790-A1 | Promoting whole body health | IFNG, TNF, TLR6 | ATP4A 2406/4885ATP4B 3360/4885MAPT 4679/4885 |
| US-20050042283-A1 | Histamine and CCK2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer | HRH2, CCKBR, GRPR | ATP4A 1168/4885ATP4B 1661/4885MAPT 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.